Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology (FATH), Université catholique de Louvain (UCL), Brussels 1200, Belgium
Valéry L. Payen
Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology (FATH), Université catholique de Louvain (UCL), Brussels 1200, Belgium
Jhudit Pérez-Escuredo
Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology (FATH), Université catholique de Louvain (UCL), Brussels 1200, Belgium
Christophe J. De Saedeleer
Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology (FATH), Université catholique de Louvain (UCL), Brussels 1200, Belgium
Pierre Danhier
Louvain Drug Research Institute (LDRI), Biomedical Magnetic Resonance Research Group (REMA), Université catholique de Louvain (UCL), Brussels 1200, Belgium
Tamara Copetti
Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology (FATH), Université catholique de Louvain (UCL), Brussels 1200, Belgium
Suveera Dhup
Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology (FATH), Université catholique de Louvain (UCL), Brussels 1200, Belgium
Morgane Tardy
Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology (FATH), Université catholique de Louvain (UCL), Brussels 1200, Belgium
Thibaut Vazeille
Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology (FATH), Université catholique de Louvain (UCL), Brussels 1200, Belgium
Caroline Bouzin
Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology (FATH), Université catholique de Louvain (UCL), Brussels 1200, Belgium
Olivier Feron
Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology (FATH), Université catholique de Louvain (UCL), Brussels 1200, Belgium
Carine Michiels
URBC-NARILIS, University of Namur, Namur 5000, Belgium
Bernard Gallez
Louvain Drug Research Institute (LDRI), Biomedical Magnetic Resonance Research Group (REMA), Université catholique de Louvain (UCL), Brussels 1200, Belgium
Pierre Sonveaux
Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology (FATH), Université catholique de Louvain (UCL), Brussels 1200, Belgium
Metastatic progression of cancer is associated with poor outcome, and here we examine metabolic changes underlying this process. Although aerobic glycolysis is known to promote metastasis, we have now identified a different switch primarily affecting mitochondria. The switch involves overload of the electron transport chain (ETC) with preserved mitochondrial functions but increased mitochondrial superoxide production. It provides a metastatic advantage phenocopied by partial ETC inhibition, another situation associated with enhanced superoxide production. Both cases involved protein tyrosine kinases Src and Pyk2 as downstream effectors. Thus, two different events, ETC overload and partial ETC inhibition, promote superoxide-dependent tumor cell migration, invasion, clonogenicity, and metastasis. Consequently, specific scavenging of mitochondrial superoxide with mitoTEMPO blocked tumor cell migration and prevented spontaneous tumor metastasis in murine and human tumor models.